M. Tullii Ciceronis opera, omnium quae hactenus excusa sunt castigatissima, nunc primum in lucem edita (a Petro Victorio). Quartus tomus, in quo Marci Tullii Ciceronis opera philosophica

Comprend : Explicationes suarum in Ciceronem castigationum

M. Tullii Ciceronis opera, omnium quae hactenus excusa sunt castigatissima, nunc primum in lucem edita (a Petro Victorio). Tertius tomus Marci Tullii Ciceronis epistolarum libros continet

Comprend : Explicationes suarum in Ciceronem castigationum

M. Tullii Ciceronis opera, omnium quae hactenus excusa sunt castigatissima, nunc primum in lucem edita (a Petro Victorio). Petri Victorii explicationes suarum in Ciceronem castigationum. - Index omnium qui hactenus excusi sunt

Comprend : Explicationes suarum in Ciceronem castigationum

Médaille décernée à Henri Labrouste, à l'école des Beaux-Arts, en 1823 / E. Gatteaux

Ancien possesseur : Labrouste, Henri (1801-1875)

Reliure de : M. Annaei Lucani pharsalia, sive de bello civili Caesaris et Pompeii lib. X. Ex emendatione V.C. Hug : Grotii.

[La guerre civile (latin). 1626]

Reliure de : Luciani Samosatensis Opera quae quidem extant omnia, e graeco sermone in latinum, partim jam olim diversis autoribus, partim nunc demum per Jacobum Micyllum, quaecunque reliqua fuere translata. Cum argumentis et annotationibus ejusdem passim adjectis... Francoforti, apud Chrisitanum Egenolphum Hadamarium. - "A la fin" : Francoforti, Christianus Aegenolphus excudebat, mense martio, anno M.D.XXXVIII

Numérisation partielle de reliure

EZ-IO(®) intraosseous device implementation in a pre-hospital emergency service: A prospective study and review of the literature.

INTRODUCTION: Intraosseous access is increasingly recognised as an effective alternative vascular access to peripheral venous access. We aimed to prospectively study the patients receiving prehospital intraosseous access with the EZ-IO(®), and to compare our results with those of the available literature. METHODS: Every patient who required an intraosseous access with the EZ-IO from January 1st, 2009 to December 31st, 2011 was included. The main data collected were: age, sex, indication for intraosseous access, localisation of insertion, success rate, drugs and fluids administered, and complications. All published studies concerning the EZ-IO device were systematically searched and reviewed for comparison. RESULTS: Fifty-eight patients representing 60 EZ-IO procedures were included. Mean age was 47 years (range 0.5-91), and the success rate was 90%. The main indications were cardiorespiratory arrest (74%), major trauma (12%), and shock (5%). The anterior tibia was the main route. The main drugs administered were adrenaline (epinephrine), atropine and amiodarone. No complications were reported. We identified 30 heterogeneous studies representing 1603 EZ-IO insertions. The patients' characteristics and success rate were similar to our study. Complications were reported in 13 cases (1.3%). CONCLUSION: The EZ-IO provides an effective way to achieve vascular access in the pre-hospital setting. Our results were similar to the cumulative results of all studies involving the use of the EZ-IO, and that can be used for comparison for further studies.

Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired stem cell disorder, with its primary clinical manifestations being hemolytic anemia, marrow failure and thrombophilia. Chronic hemolysis, failures of the fibrinolytic system, increased leukocyte-derived tissue factor levels in plasma, procoagulant microparticles generated through complement-mediated damage of platelets and venous endothelium are related to the acquired hypercoagulable state. Visceral thrombosis (including hepatic veins and mesenteric veins), cerebrovascular events and pulmonary embolism predict a poor outcome. Thrombosis is also associated with significant morbidity during pregnancy. Depending on the sites of thrombosis, a score-based probability to predict outcome can be assigned. Abdominal vein thromboses account for the majority of morbidity and mortality related to thrombosis, and time-dependent trends suggest that mortality rates tend to decline, with the advent of evolution of therapeutic and diagnostic strategies. In contrast, mortality rates from cerebrovascular events display no significant decline. Prompt diagnosis requires both clinical suspicion and sophisticated imaging techniques, along with multidisciplinary therapeutic intervention. In the eculizumab era, a significant reduction of thrombotic events was observed during therapy, and long-term follow up is needed to establish any benefit in rates and pattern of this complication. However, up to now, only bone marrow transplantation permanently abolishes the coagulation defect.